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Introduction: Patients with Von Willebrand disease (VWD) are regularly treated with 
VWF- containing concentrates in case of acute bleeding, trauma and dental or surgi-
cal procedures.
Aim: In this multicentre retrospective study, current perioperative management with 
a von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate (Haemate® P) in 
 patients with VWD was evaluated.
Patients/Methods: Patients with VWD undergoing minor or major surgery between 
2000 and 2015, requiring treatment with a VWF/FVIII concentrate (Haemate® P), 
were included. Achieved VWF activity (VWF:Act) and FVIII during FVIII- based treat-
ment regimens were compared to predefined target levels in national guidelines.
Results: In total, 103 patients with VWD (148 surgeries) were included: 54 type 1 (73 
surgeries), 43 type 2 (67 surgeries) and 6 type 3 (8 surgeries). Overall, treatment re-
sulted in high VWF:Act and FVIII levels, defined as ≥0.20 IU/mL above predefined 
levels. In patients with type 1 VWD, respectively, 65% and 91% of trough VWF:Act 
and FVIII levels were higher than target levels. In patients with type 2 and type 3 
VWD, respectively, 53% and 57% of trough VWF:Act and 72% and 73% of trough 
FVIII levels were higher than target level. Furthermore, FVIII accumulation over time 
was observed, while VWF:Act showed a declining trend, leading to significantly 
higher levels of FVIII than VWF:Act.
Conclusion: High VWF:Act and accumulation of FVIII were observed after periopera-
tive FVIII- based replacement therapy in patients with VWD, both underlining the ne-
cessity of personalization of dosing regimens to optimize perioperative treatment.
K E Y W O R D S
individualized medicine, surgery, therapy, von Willebrand Disease, von Willebrand factor 
(MESH entry database)
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1  | INTRODUC TION
Von Willebrand disease (VWD) is the most common inherited bleed-
ing disorder with an estimated prevalence of approximately 1% with 
clinically relevant bleeding in 0.01%.1 It is caused by a quantitative or 
qualitative defect of von Willebrand factor (VWF) and is characterized 
by mucocutaneous bleeding and bleeding after trauma or surgery.2 In 
more severe VWD, there also may be a concomitant factor VIII (FVIII) 
deficiency, as VWF prevents FVIII from proteolysis.3 Generally, pa-
tients with VWD are treated with desmopressin (DDAVP) or VWF- 
containing concentrates when acute bleeding or trauma occurs, or 
to prevent bleeding in the surgical setting. The aim of treatment is to 
correct the VWF deficiency, and also to correct a FVIII deficiency, if 
this is present. In patients who do not respond adequately to DDAVP 
or have contra- indications for its use, treatment usually consists of 
combined VWF/FVIII factor concentrates amongst which the ratios 
of VWF activity (VWF:Act) over FVIII may differ.4
Although clinical symptoms are generally milder than in haemo-
philia, dosing of perioperative treatment in VWD is more challenging 
due to variation in VWD types and mutations,2,5 interpatient vari-
ability of residual endothelial VWF production, VWF secretion and 
clearance, as well as heterogeneity in types of factor concentrates 
with different ratios of VWF:Act/FVIII and VWF:Act/VWF antigen 
(VWF:Ag).6,7 Previous studies have, however, reported that surgical 
procedures can be performed safely in patients with VWD and that 
treatment with VWF- containing concentrates is efficacious.8-17
In many countries, specific target levels are defined in national 
guidelines to safeguard haemostasis during surgery. These target 
values are based on expert opinion and limited observational re-
search (Figure 1).18 Currently, calculation of the required doses of 
VWF and/or FVIII is based on body weight. In the Netherlands, dos-
ing is FVIII level- based, due to the fact that FVIII is considered cru-
cial in preventing surgical bleeding by its role in thrombin generation 
and consolidation of the fibrin plug.17 However, momentarily VWF 
levels are increasingly monitored as rapid availability of VWF activ-
ity assay results is becoming mainstream. This may facilitate a more 
VWF- based dosing regimen in the near future.19 Furthermore, it is 
increasingly common to label factor concentrates according to both 
FVIII and VWF content.
VWF/FVIII concentrates can be classified into three different 
groups according to VWF:Act/FVIII and VWF:Act/VWF:Ag ra-
tios7 Firstly, products with a VWF:Act/FVIII ratio of approximately 
1 (with low or high VWF:Act/VWF:Ag ratio). Secondly, with a 
VWF:Act/FVIII ratio of >1 (with high VWF:Act/VWF:Ag ratio) and 
lastly, VWF concentrates with a VWF:Act/FVIII ratio of >10 (with 
also high VWF:Act/VWF:Ag ratio). In case the last concentrates are 
used perioperatively, patients with low circulating FVIII levels should 
receive this concentrate intravenously 6- 8 hours before surgery, to 
allow endogenous FVIII to rise to haemostatically adequate levels. 
Therefore, in emergency situations, a priming dose of FVIII in ad-
dition to VWF concentrate is often required.20 Because FVIII pro-
duction and secretion are normal in patients with VWD, infusion of 
exogenous VWF, which stabilizes and increases endogenous FVIII 
levels, together with exogenous FVIII, may lead to very high levels 
of FVIII (>2.70 IU/mL).21 This is, of course, a possible risk factor for 
thrombosis.22 It has been demonstrated that repetitive dosing of 
concentrates with a VWF:Act/FVIII ratio >1 will result in less accu-
mulation of FVIII than concentrates with a ratio of approximately 
1.8 Worldwide, the most frequently used VWF/FVIII concentrate is 
Haemate® P, a plasma- derived virus- inactivated VWF/FVIII concen-
trate with a VWF:RCo/FVIII ratio of 2.45.23
Choice of perioperative treatment is dependent on type and se-
verity of VWD, while dosing of replacement therapy is dependent on 
type and extent of the surgical procedure.18 In addition, treatment 
may differ due to interindividual differences in pharmacokinetic 
(PK) parameters such as clearance and half- life of both exogenous 
and endogenous VWF and FVIII. Studies report that perioperative 
VWF/FVIII concentrate consumption indeed varies substantially, 
from 27 to 146 VWF:Act IU/kg/day8,17. As achieved VWF and FVIII 
levels have rarely been evaluated and reported in relation to effi-
cacy,24 we aimed to evaluate current perioperative management 
with VWF/FVIII concentrate in patients with VWD in relation to 
target levels as stated in national guidelines. This was done by as-
sessing the extent to which predefined VWF:Act and FVIII target 
levels were actually achieved as well as by analysis of predictors of 
higher or lower VWF:Act and FVIII levels than targeted. Insight in 
these factors will help realize more efficacious and individualized 
treatment in VWD. In addition, collection of these data will help 
construct population PK models for patients with VWD in the near 
future.
2  | MATERIAL S AND METHODS
This multicentre retrospective observational cohort study was 
conducted in five Academic Haemophilia Treatment Centres in 
the Netherlands (Erasmus University Medical Centre Rotterdam 
(n = 51); Academic Medical Centre Amsterdam (n = 15); University 
Medical Centre Groningen (n = 14); Leiden University Medical 
Centre (n = 12) and Radboud university medical centre (n = 11). This 
study was not subject to the Medical Research Involving Human 
Subjects Act, as retrospective, anonymized data were analyzed and 
therefore, according to Dutch law, review by the Ethical Committee 
and informed consent were not required.
2.1 | Subject selection
Patients with a clinical and laboratory diagnosis of VWD (historically 
lowest levels of VWF:Ag ≤0.30 IU/mL and/or VWF:Act ≤0.30 IU/mL 
and/or FVIII ≤0.40 IU/mL) were included. Patients who underwent 
a minor or major surgical procedure as defined by Koshy et al.,25 
under replacement therapy with a plasma- derived VWF/FVIII con-
centrate between January 1st 2000 and January 1st 2015, were 
eligible. Only patients treated with Haemate® P, the most widely 
used concentrate for treatment of VWD in the Netherlands, were 
included. Monitoring of minimally two VWF:Act and FVIII levels was 
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obligatory for inclusion. Patients with other known haemostatic dis-
orders and patients lacking accurate documentation were excluded.
2.2 | Study objective
The study objective was to evaluate current perioperative manage-
ment with a specific VWF/FVIII factor concentrate (Haemate® P) in 
patients with VWD by specification of concentrate administration 
and analysis of subsequently achieved peak and trough levels of 
VWF:Act and FVIII in comparison with target VWF and FVIII levels 
as prescribed by national guidelines (Figure 1).18 In this study, both 
potential predictors of low and high levels of VWF:Act and FVIII as 
well as variables associated with VWF/FVIII concentrate consump-
tion were collected and evaluated.
2.3 | Laboratory assessment
VWF:Act and FVIII were generally monitored daily during hospitali-
zation. Immediately before surgery, peak levels were assessed and 
in the days after surgery trough levels were measured once or twice 
daily. In all cases, perioperative dosing was based on FVIII levels, as 
VWF:Act results were generally not or not rapidly available. FVIII 
was measured by one- stage clotting assays in all participating cen-
tres. In various centres, different VWF activity (VWF:Act) assays 
were performed according to local protocol.
2.4 | Data collection
Patient, surgical and treatment characteristics during the hospitali-
zation period were collected retrospectively. Patient characteristics 
included age, body weight, gender, type of VWD, baseline VWF:Ag, 
VWF:Act and FVIII (historically lowest level), ABO blood group and 
VWF gene mutation if available. Surgical characteristics consisted of 
procedure severity as classified by surgical risk score,25 duration of 
surgery, perioperative blood loss and postsurgical bleeding complica-
tions. Bleeding complications were assessed according to definition 
by the International Society of Thrombosis and Haemostasis26 and 
defined as necessity of second surgical intervention, haemoglobin 
decrease ≥1.24 mmol/L and/or requiring red blood cell transfusion, 
or bleeding prolonging patient hospitalization. A clinically relevant 
bleeding complication was defined as a bleeding complication re-
quiring a second surgical intervention and/or red blood cell transfu-
sion. Treatment characteristics included timing and dosing of VWF/
FVIII concentrate administration and achieved VWF:Act and FVIII 
during and after surgical procedure, mode of infusion (continuous 
or bolus infusion) of VWF/FVIII concentrate and co- medication with 
effect on haemostasis (desmopressin, tranexamic acid, low molecu-
lar weight heparin, non- steroidal anti- inflammatory drugs) as well as 
duration of hospitalization. Duration of hospitalization was defined 
as day of discharge minus day of surgical procedure and initiation of 
replacement therapy with VWF/FVIII concentrate.
F IGURE  1 Target VWF:Act and FVIII 
in VWD patients in the perioperative 
setting. According to National 
guidelines18. Guidelines describe a 
standard perioperative dosing regimen 
of patients with VWD undergoing 
minor or major surgery. A loading dose 
of VWF/FVIII factor concentrate of 
50 IU/kg FVIII (30- 50 IU/kg in case of 
minor surgery) followed by maintenance 
doses of 15- 25 IU/kg FVIII twice daily, 
depending on FVIII measurements. Both 
VWF:Act and FVIII are targeted at trough 
and/or steady- state levels
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2.5 | National guideline and evaluation of 
perioperative VWF/FVIII concentrate management
National guidelines prescribe a FVIII- based regimen with a loading 
dose of VWF/FVIII concentrate (ratio of 2.4:1) of 50 IU/kg FVIII for 
major surgery and 30- 50 IU/kg FVIII for minor surgical interventions 
followed by maintenance doses of 15- 25 IU/kg FVIII twice daily with 
regular monitoring of VWF:Act and FVIII, although no definition of 
regular monitoring is given. Frequency and timing of monitoring is 
left to the expertise of the treating physician and depends on VWD 
type, type and severity of surgery and bleeding phenotype. Dosing 
is adjusted according to VWF:Act and FVIII target levels specified 
in guidelines and depicted in Figure 1.18 In general, patients are 
treated 7- 10 days in case of a major surgical procedure and 4- 7 days 
in case of a minor surgical procedure. This is in accordance with the 
UKHCDO and Nordic guidelines.27,28 Perioperative dosing was left 
to discretion of treating physician. When patients were prescribed 
thromboprophylaxis, in the majority of patients low molecular 
weight heparin was used. Thromboprophylaxis was given at the dis-
cretion of the treating physician, taking type of surgery, duration of 
hospitalization and patient risk factors for thrombosis, such as age, 
body mass index, history of thrombosis and genetic predisposition 
for thrombosis into account.
Perioperative management with VWF/FVIII concentrate after 
first peak values was evaluated by comparing achieved VWF:Act 
and FVIII trough and steady- state levels to target VWF:Act and FVIII 
levels. Trough levels were defined as measurements prior to bolus 
infusion or measurements at least 12 hours after infusion, when no 
subsequent factor concentrate infusion was given. Redundantly, 
no peak levels after bolus infusion were included in these analyses. 
Steady- state samples were defined as VWF and FVIII levels sampled 
when concentrate substitution is expected to equal elimination of 
VWF/FVIII concentrate when administered by continuous infusion. 
In general, it is assumed that steady state will be reached after a load-
ing dose has been administered and continuous infusion has started.
Analysis of predictors of low and high levels of VWF:Act/FVIII 
could only be performed in patients with type 1 and type 2 VWD, 
due to limited numbers of patients with type 3 VWD. A stepwise 
backward and forward logistic regression analysis was performed 
with low levels defined as VWF:Act or FVIII below predefined tar-
get levels stated by guidelines, and high levels as all VWF:Act or 
FVIII levels above the predefined target level with a deviation of 
≥0.20 IU/mL. Potential predictors for low and high VWF:Act or 
FVIII levels in the analysis were severity of surgical procedure, 
blood group O vs non- O, body weight, age, mode of infusion and 
treatment centre.
2.6 | Statistical analysis
Descriptive data are presented as numbers with percentages for cat-
egorical variables and as medians with an interquartile range (IQR) 
for continuous variables, as data were not normally distributed. The 
non- parametric Mann- Whitney U test was used to compare VWF/
FVIII concentrate consumption between surgical procedures of dif-
ferent severity. If a patient was subjected to two or more surgeries, 
calculations were only performed for the first surgical procedure. 
Potential predictors of lower and higher VWF:Act/FVIII levels than 
aimed for were analyzed by stepwise backward and forward logistic 
regression analysis with elimination of variables with P > .10. A linear 
regression analysis was performed to calculate if FVIII accumulation 
occurred after repetitive dosing of VWF/FVIII concentrate, whereby 
regression coefficients were compared between both VWF:Act and 
FVIII. Data management and statistical analysis were performed with 
IBM SPSS statistics for Windows, version 23.0 (IBM Corp, Armonk, 
NY, USA). A P- value of <.05 was considered statistically significant.
3  | RESULTS
The study population consisted of 103 patients undergoing a total of 
148 surgical procedures; 54 patients with type 1 VWD (73 surgical 
procedures), 43 patients with type 2 VWD undergoing 67 proce-
dures in total: 24 type 2A patients (34 procedures), 7 type 2B pa-
tients (8 procedures), 3 type 2N patient (8 procedures) and 9 type 
2M patients (17 procedures) and 6 patients with type 3 VWD (8 sur-
gical procedures) (Table 1). Half of patients had blood group O (51%). 
Median historical lowest measured VWF:Ag level and VWF:Act level 
were 0.30 and 0.22 IU/mL for patients with type 1 VWD; 0.29 and 
0.10 IU/mL for type 2 VWD and 0.05 and <0.10 IU/mL (lower than 
detection limit) for patients with type 3 VWD. Median historical low-
est measured FVIII level was 0.54 IU/mL for type 1, 0.42 IU/mL for 
type 2 and 0.03 IU/mL for patients with type 3 VWD. Some patients 
in the study population underwent multiple surgical procedures 
(Table 1). Procedures were mainly orthopaedic (n = 36; 24%), gen-
eral (n = 26; 18%) and gynaecological (n = 24; 16%). No differences 
in number and type of surgical procedures between VWD types 
were observed. Almost all patients received replacement therapy by 
bolus infusion (90%). Median duration of hospitalization was 6 days 
(Table 1). Eleven (29%) and 52 (47%) patients with respectively a 
minor and major surgical procedure received thromboprophylaxis 
with low molecular weight heparin. In 51 surgical procedures, pa-
tients received tranexamic acid.
3.1 | Actual VWF:Act and FVIII levels compared to 
predefined target levels
No differences were observed in achieved VWF:Act and FVIII 
levels between patients with type 1, type 2 and type 3 VWD 
(Figure 2) after replacement therapy. In all VWD types, most peri-
operative VWF:Act and FVIII levels were well above predefined 
target levels. Postoperatively, accumulation of FVIII was observed 
after repetitive dosing of VWF/FVIII concentrate, resulting in in-
creased FVIII in comparison with VWF:Act (P < .01) (Figure 3). No 
differences in FVIII accumulation were observed between type 1 
and type 2 (data not shown). Thirteen (8%) FVIII trough levels were 
above 2.70 IU/mL.
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In the 54 patients with type 1 VWD, in the first 36 hours after 
surgery, median trough VWF:Act was 1.48 IU/mL (IQR 1.03- 1.87). 
Eighty- four percent of trough and steady- state levels were above 
predefined target level with a median deviation of 0.80 IU/mL 
(IQR 0.38- 1.11). Seven levels were below target level (median de-
viation: 0.24 IU/mL [IQR 0.03- 0.38]). All these patients underwent 
a major surgical procedure and received an additional bolus infu-
sion with VWF/FVIII concentrate to correct lower levels. With re-
gard to FVIII, median trough and steady state was 1.46/IU mL (IQR 
1.14- 1.82) in this time period. Ninety- two per cent of measured 
levels were above predefined target level, with a median deviation 
of 0.70 IU/mL (IQR 0.43- 1.07). Only in five patients (9%) FVIII was 
below the predefined target level. All received additional treat-
ment: in four patients this consisted of VWF/FVIII concentrate 
and in one patient of intravenous desmopressin. In the period from 
36 hours until 72 hours after surgery, all trough and steady- state 
FVIII levels were above FVIII target level (median FVIII 1.80 IU/
mL [IQR 1.35- 2.11]).
TABLE  1 General characteristics of study population
N (%) or median [IQR]
Patients Total Type 1 Type 2 Type 3
No. of patients 103 (100) 54 (100) 43 (100)a 6 (100)
Female gender 69 (67) 38 (70) 27 (63) 4 (67)
Age (years) 51 [36- 62] 52 [40- 61] 53 [36- 66] 22 [16- 33]
Height (cm) 175 [167- 180] 173 [166- 179] 175 [165- 183] 179 [168- 180]
Body weight (kg) 77 [65- 85] 79 [68- 89] 75 [62- 83] 74 [65.7- 78.5]
Body mass index (kg/m2) 24.9 [22.7- 28.1] 25.4 [23.6- 29.1] 24.2 [21.7- 25.7] 22.5 [21.2- 26.2]
Blood group O 51 (50) 32 (59) 16 (37) 3 (50)
Baseline VWF/FVIII levelsb
Antigen (IU/mL) 0.28 [0.21- 0.38] 0.30 [0.22- 0.38] 0.29 [0.22- 0.39] 0.05 [0.01- 0.06]
Activity (IU/mL) 0.14 [0.10- 0.25] 0.22 [0.13- 0.30] 0.10 [0.05- 0.15] 0.10 [0.04- 0.10]c
FVIII (IU/mL) 0.44 [0.28- 0.60] 0.54 [0.34- 0.69] 0.42 [0.24- 0.57] 0.03 [0.02- 0.08]
Surgery
No. of surgical procedures 148 (100) 73 (100) 67 (100) 8 (100)
Total number of patients undergoing
1 procedure 75 (73) 41 (76) 29 (67) 5 (83)
2 procedures 16 (15) 7 (13) 9 (21) 0 (0)
3 procedures 10 (10) 6 (11) 3 (7) 1 (17)
≥4 procedures 2 (2) 0 (0) 2 (5) 0 (0)
Severity of surgical procedure
Minor 38 (26) 13 (18) 18 (27) 7 (88)
Major 110 (74) 60 (82) 49 (73) 1 (12)
Treatment
Duration hospitalization (days) 6 [4- 8] 6 [4- 8] 6 [3- 9] 7 [3- 8]
Type of infusion
Bolus infusion 133 (90) 64 (88) 62 (93) 7 (88)
No. of complications
Bleeding 20 (14) 12 (16) 8 (12) 0 (0) 
Re- operation 1 (5) 0 (0) 1 (11) 0 (0) 
Hemoglobin drop ≥1.24 mmol/L 
and/or RBCTF
19 (95) 12 (100) 7 (89) 0 (0) 
Prolonged hospitalization 0 (0) 0 (0) 0 (0) 0 (0) 
Thrombosis 0 (0) 0 (0) 0 (0) 0 (0) 
No., number (percentages); Median, [IQR = Inter quartile range 25%- 75%]; cm, centimetre; kg, kilogram; kg/m2, kilogram per square meter; VWF, von 
Willebrand factor; IU/mL, international units per millilitre; mmol/L, millimol per litre; RBCTF, red blood cell transfusion.
a24 type 2A, 7 type 2B, 3 type 2N and 9 type 2M patients.
bHistorically lowest measured VWF/FVIII levels.
cVWF: Act measurements were lower than the limit of detection 0.10 IU/mL in a number of VWD type 3 patients.
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F IGURE  2 Achieved VWF:Act and 
FVIII in the perioperative period. The 
red lines indicate predefined target 
VWF:Act and FVIII according to national 
guidelines18. Preoperative peak VWF:Act 
and FVIII levels are shown <0 hours. 
Postoperative trough and steady- state 
VWF:Act and FVIII measurements are 
shown after surgery. Start of surgical 
procedure was defined as t = 0 hours. 
(A) Achieved VWF:Act and (B) Achieved 
FVIII levels. No differences in achieved 
VWF:Act and FVIII are observed between 
types of VWD
(A)
(B)
F IGURE  3 Accumulation of FVIII 
after repetitive dosing of VWF/FVIII 
concentrate. Accumulation of FVIII 
was present after repetitive dosing 
of VWF/FVIII concentrates, resulting 
in increased FVIII in comparison with 
VWF:Act (P < .01) (F = 6.90 DFn = 1, 
DFd = 209); Haemate® P
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Overall, no differences in achieved VWF:Act and FVIII were 
observed for minor versus major surgical procedures, blood group 
non- O versus O, adults versus children and between modes of infu-
sion (data not shown). Moreover, high VWF:Act and FVIII levels (de-
fined as >0.20 IU/mL above target) were predominant as illustrated 
by the fact that 65% of trough and steady- state VWF:Act levels, and 
91% of FVIII values were above target.
In the 43 patients with type 2 and 6 patients with type 3 VWD, 
62% and 71% of trough VWF:Act levels were above predefined tar-
get level in the first 36 hours after surgery (not significantly differ-
ent from type 1 VWD). Median VWF:Act in this period was 1.07 IU/
mL [IQR 0.68- 1.50] and 1.30 IU/mL [IQR 0.82- 1.68], respectively. 
Eighty- six per cent and 89% of trough FVIII were above target in 
the first 36 hours with a median deviation of 0.40 IU/mL [IQR 0.26- 
0.85] and 0.47 IU/mL [IQR 0.28- 0.71], respectively, for patients with 
type 2 and type 3 VWD. In addition, all FVIII were above target after 
36 hours of hospitalization for both minor and major surgical proce-
dures. High VWF:Act and FVIII (≥0.20 IU/mL) were present in 53% 
and 57% of VWF:Act and in 72% and 73% of FVIII for patients with 
type 2 and type 3 VWD, respectively.
3.2 | Bleeding complications
Overall, occurrence of bleeding complications was not associated 
with a low trough VWF:Act and/or low FVIII (P = .95 and 0.25 respec-
tively). Exception was one patient, undergoing a craniotomy with 
excessive blood loss with need for blood cell transfusions and pre-
senting with lower trough VWF:Act (0.40 IU/mL) and FVIII (0.60 IU/
mL) levels (Table 2). Clinically relevant bleeding only occurred in 5 
(3.4%) surgical procedures, as four surgical procedures required red 
blood cell transfusion post surgery and only one a second surgical 
intervention (Table 2). Despite excessive FVIII levels, no thrombotic 
complications were reported. Of the 18 patients reaching very high 
(>2.70 IU/mL) FVIII levels, 61% received thromboprophylaxis with 
low molecular weight heparin.
3.3 | Treatment
Two patients with type 1 VWD received only desmopressin prior to 
surgery to achieve VWF:Act and FVIII target levels. After surgery, 
trough VWF:Act and FVIII were 0.56/0.55 and 0.59/0.48 IU/mL, re-
spectively. Consecutively, the treating physician administered VWF/
FVIII concentrate on following postoperative days. Four patients 
with type 1 VWD received desmopressin as well as Haemate® P be-
fore start of surgery. In the postoperative period, desmopressin was 
administered in 7 patients with type 1 VWD and 1 type 2A VWD 
patient.
In patients with type 1 and type 2 VWD, median loading dose 
for minor and major surgical procedures did not differ (Figure 4). In 
patients with type 1 VWD, maintenance dose on day 1 (0- 24 hours) 
after surgery differed between minor and major procedures with a 
significantly higher dose in cases of minor surgery (33 and 26 IU/kg 
respectively, P = .048). No differences between minor and major T
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surgical procedures were observed for loading and maintenance 
doses in type 2 VWD. Loading dose and maintenance doses did not 
differ between patients with type 1 and type 2 VWD, as median for 
loading doses was 36 IU/kg [IQR 27- 49] and 43 IU/kg [IQR 37- 52], 
P = .12, and median maintenance doses ranged from 22- 27 IU/kg 
to 21- 35 IU/kg. Patients who underwent a minor procedure were 
generally treated with VWF/FVIII concentrate for a median duration 
of 48 hours. Median duration of hospitalization for patients under-
going a minor or major surgical procedure did not differ significantly 
(respectively, 4 [IQR 4- 8] versus 6 [IQR 4- 8] days, P = .88).
3.4 | Predictors of low and high VWF:Act and 
FVIII levels
It was only possible to evaluate predictors in patients with type 1 and 
type 2 VWD, due to a limited number of type 3 patients. This was 
performed for both VWF:Act and FVIII by both stepwise backward 
logistic regression analysis as well as stepwise forward logistic re-
gression analysis. In type 1 VWD, in the total postoperative period, 
only blood group O was predictive of high VWF:Act levels (VWF:Act 
levels ≥0.20 IU/mL above target) (OR 2.9; 95%CI [1.3- 6.6]); not of 
high FVIII levels. No other predictors were found for low and high 
VWF:Act and FVIII levels in both patients with type 1 and type 2 
VWD.
4  | DISCUSSION
This study is the largest so far evaluating perioperative manage-
ment of patients with VWD in a resource- rich country. We present 
data that underline the complexity of VWF/FVIII concentrate dos-
ing in this patient population, as illustrated by the fact that in pa-
tients with type 1 VWD, 65% of trough and steady- state VWF:Act 
and 91% of FVIII levels were ≥0.20 IU/mL above predefined target 
F IGURE  4 Loading and maintenance 
doses in minor and major surgical 
procedures in patients with type 1 and 
type 2 VWD. Loading and maintenance 
doses in minor and major surgical 
procedures are shown using a scatter 
dot plot with median and 5%- 95% 
quartile ranges for (A) Patients with 
Type 1 and (B). Type 2 VWD. The non- 
parametric Mann- Whitney U test was 
used to compare VWF/FVIII concentrate 
consumption between minor and major 
surgical procedures
(A)
(B)
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levels. In type 2 and type 3 VWD, respectively, 53% and 57% of 
VWF:Act and 72% and 73% of FVIII were ≥0.20 IU/mL above pre-
defined target levels. In contrast to results in perioperative severe 
and moderate haemophilia A patients,29 only a small percentage 
of patients with VWD experienced low levels in the first 36 hours 
after surgery, as only 16% of VWF:Act levels in patients with type 
1 VWD and 38% and 29% of VWF:Act levels in patients with type 
2 and 3 VWD, respectively, and only 8%, 14% and 11% of FVIII 
levels in, respectively, type 1, type 2 and type 3 VWD were below 
prescribed target level. This is probably due to FVIII- based dos-
ing performed according to the Dutch national guidelines applied 
in this study. Although both VWF:Act and FVIII were measured 
perioperatively, VWF:Act was not directly available in most cases 
and could not be used to monitor perioperative VWF/FVIII con-
centrate management. In our cohort, prevalence of clinically rel-
evant bleeding complications was low (3.4%) and not associated 
with achieved VWF:Act and/or FVIII. This is supported by oth-
ers9,13,15,16,30 and confirms that other causal factors for bleeding 
than VWF:Act and FVIII, either haemostatic or surgical must be in-
volved. In this study, no predictors of bleeding could be identified. 
Strikingly, blood group O was predictive of high VWF:Act levels 
(≥0.20 IU/mL above target) in type 1 VWD in the total postopera-
tive period. Most probably this is explained by lower endogenous 
baseline VWF:Act and FVIII levels resulting in administration of 
higher dosages of VWF/FVIII concentrates. A limitation of this 
retrospective study, depicting real- life data, is that in the different 
centres, different assays were used and may have been altered 
during the study period. Therefore, one should keep in mind that 
interassay variability may have influenced the generalizability of 
the results in terms of plasma FVIII and VWF levels. Furthermore, 
as no clear definition of regular monitoring is given in the guide-
lines, amount and timing of FVIII and VWF:Act measurements 
differed between occasions. When evaluating only major surgical 
procedures, VWF:Act and/or FVIII was measured <24 hours be-
fore surgery in 89% of occasions, with emergency surgery as a 
partial explanation for the missing measurements. In 78% of oc-
casions, VWF:Act and/or FVIII was measured at least once within 
24 hours after start of the procedure, and in 57% of occasions 
within 24- 48 hours after start of surgery, if the patient was still 
hospitalized. There were no clear differences in the amount or tim-
ing of the measurements between centres.
Analyses were performed for the total VWD population as well 
as separately for each type of VWD, as it has been shown that clear-
ance mechanisms of the endogenous VWF differ between VWD 
types.2,5 However, no differences were found in achieved VWF:Act 
and FVIII level after preoperative loading and subsequent mainte-
nance doses between type 1 and type 2 VWD. Also, VWF/FVIII con-
sumption did not differ between types of VWD. Counterintuitively, 
on day 1 (0- 24 hours) after surgery, a significantly higher VWF/FVIII 
concentrate consumption was observed for minor surgical proce-
dures when compared to major surgical procedures. This is proba-
bly explained by the fact that patients undergoing a minor surgical 
procedure received less frequent but higher dosed bolus infusions 
within a shorter period of time. This finding is supported by a previ-
ous study in 29 patients with type 1, 2A, 2M and 3 VWD in which no 
differences in concentrate consumption between patients undergo-
ing minor or major surgical procedures were observed.13
In this perioperative study, accumulation of FVIII was observed 
after repetitive dosing of VWF/FVIII concentrate, with median FVIII 
values increasing with time (Figure 3). Increasing FVIII levels, due 
to concomitant increase in both endogenous and exogenous FVIII, 
were significantly higher than VWF:Act levels (P < .01). This may 
be partly explained by findings by Kahlon et al.31 who observed an 
intraoperative decrease and postoperative increase in VWF and 
FVIII levels in 30 individuals without a bleeding disorder undergo-
ing surgery. In these healthy individuals, mean VWF:Act and FVIII 
levels were greater than 1.00 IU/mL at all intra- and postoperative 
time points. This physiological response to surgery may reflect an 
increased need of VWF in the perioperative period. Current guide-
lines are not in line with these physiological responses to surgery, 
as perioperative target VWF:Act and FVIII levels are >0.80 IU/mL 
(0- 36 hours postoperatively) and >0.30/0.50 IU/mL (36- 240 postop-
eratively) and thus below 1.00 IU/mL.
Although we observed high FVIII levels that confer a possible risk 
for thrombosis,22,32,33 no thrombo- embolic complications were ob-
served. Previously, Wells et al. demonstrated that FVIII levels above 
2.70 IU/mL are associated with a higher risk of thrombosis in non- 
surgical patients.21 In our study, 8% of trough levels of FVIII were 
above 2.70 IU mL. Also, observed postoperative VWF:Act and FVIII 
levels were increased for only a brief period of time and coincide 
with physiological levels in healthy individuals without a bleeding 
disorder.31 Mannucci et al. also reported this scarcity of thrombo-
sis in perioperative VWD patients on replacement therapy.32 In our 
study, it must also be taken into account that almost half of patients 
undergoing a major surgical procedure received thromboprophylaxis 
with low molecular weight heparin.
As reported, plasma- derived VWF/FVIII concentrate in this 
study (Haemate P®), has a VWF:Act/FVIII ratio of 2.4:1 and con-
tains large amounts of high molecular- weight multimers, which 
are thought to be the most haemostatically potent multimers. 
Earlier, in vivo recovery (IVR) studies have demonstrated a me-
dian IVR of 2.0 for VWF:Act and FVIII, implying a rise of approx-
imately 0.02 IU/mL in VWF:Act and FVIII for each infused IU/
kg for VWF:Act or FVIII. Theoretically, for each infused IU/kg of 
FVIII an increase in approximately 0.05 IU/mL VWF:Act will be 
observed (2.4 × 0.02 IU/mL). Currently, it is common practice to 
apply IVR to dose and monitor replacement therapy.13,15 However, 
dosing based on body weight and IVR does not take interindi-
vidual differences in clearance and volume of distribution into 
account that are associated with half- life of VWF/FVIII concen-
trates. Personalized perioperative dosing based on IVR deducted 
from a preoperative PK profile is not possible, as PK profile is not 
representative for clearance during surgery as shown by Di Paola 
et al.12 In this study, only a weak correlation was shown between 
IVR values of VWF:Act obtained 1 week prior to surgery and IVR 
values obtained directly after surgery (n = 41; r = .41).12 Both the 
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changes of IVR following surgery and differences in half- life be-
tween VWD types demonstrate the complexity and importance 
of development of alternative dosing algorithms to individualize 
treatment for each patient with VWD. Hypothetically, VWD pop-
ulation PK models will be able to incorporate these differences 
between VWD types due to: mutational variation, differences in 
baseline values of endogenous VWF:Act and FVIII, higher FVIII 
levels with a longer half- life,34 differences in clearance of endog-
enous and exogenous VWF:Ag and VWF:Act and differences in 
composition of administered VWF/FVIII concentrates. Also, other 
known and unknown modifying factors that influence clearance 
and volume of distribution in an on- demand perioperative setting 
can be incorporated. The development of such models will lead 
to Bayesian adaptive dosing to predict VWF:Act and FVIII and 
effects of treatment more precisely. In the long run, we believe 
such an approach will optimize patient care and potentially re-
duce overall costs of treatment by reduction in the amount of 
total infused clotting factor concentrate.13,32,35-37 Therefore, PK- 
guided dosing forms a promising approach for more efficient and 
individualized replacement therapy in VWD with considerable 
clinical and economic impact due to the frequency of this bleed-
ing disorder.
5  | CONCLUSION
Although perioperative replacement therapy in patients with VWD 
is successful with few bleeding complications, it can be optimized as 
patients are currently overtreated with accumulation of FVIII as a 
consequence, fortunately without thrombotic complications. Due to 
the complexity of treatment in VWD, we hypothesize that popula-
tion PK models, which incorporate known and unknown modifying 
factors of clearance and other PK parameters of VWF/FVIII concen-
trates, may be promising tools for personalization of replacement 
therapy in all patients with VWD.
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